Nature Reviews Drug Discovery contents March 2016 Volume 15 Number 3 pp 145-216

If you are unable to see the message below, click here to view.

Advertisement
Key Advances in Medicine eBook from Nature Reviews - FREE to download!  This essential resource summarizes the groundbreaking clinical and biomedical discoveries of 2015 and highlights the trends to watch out for in 2016, making it a must read eBook for anyone with an interest in medical science.  Download for free
TABLE OF CONTENTS
March 2016 Volume 15 Number 3		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Single-cell analysis tools for drug discovery and development James R. Heath, Antoni Ribas & Paul S. Mischel	Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide and pomalidomide, are used to treat multiple myeloma, myelodysplastic syndrome and leprosy complications. Access this Collection free online exploring IMiDs' mechanisms of action.  Produced with support from: Celgene Corporation.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Two NO COST pilot projects to be awarded. Register for our webcast on Building Better Therapeutics with Metabolomics and be eligible to submit your abstract for 1 of 2 50 sample projects using metabolomics.  Register for the webcast free online.
Advertisement
nature.com webcasts Join us for our upcoming webcast with live Q&A: COMBATING ANTIBIOTIC RESISTANCE Presented by BioPharma Dealmakers Date: Wednesday, March 9, 2016 Time: 8AM PST, 11AM EST, 4PM GMT, 5PM CET REGISTER FOR FREE Sponsored by: Antabio, Cempra, Helperby, Motif Bio, Polyphor
Comment: The right dose for every patient: a key step for precision medicine Richard W. Peck p145 | doi:10.1038/nrd.2015.22 Understanding the basis of variability in the response of patients to the dose of a drug and a willingness to vary the dose regimen as well as the choice of drug should be one of the key pillars of precision medicine. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Pioneering apoptosis-targeted cancer drug poised for FDA approval Asher Mullard p147 | doi:10.1038/nrd.2016.23 AbbVie's BCL-2 inhibitor venetoclax — the leading small-molecule protein-protein interaction inhibitor [mdash] could soon become the first marketed drug to directly target the ability of cancer cells to evade apoptosis. PDF
Food allergy drugs step up to Phase III Katie Kingwell p149 | doi:10.1038/nrd.2016.24 Two biotechs have carved out a regulatory pathway for what could become the first FDA-approved preventative peanut allergy therapies. PDF
NEWS IN BRIEF First biosimilar antibody nears US approval Asher Mullard p151 | doi:10.1038/nrd.2016.45 PDF
BACE race gains steam Asher Mullard p151 | doi:10.1038/nrd.2016.46 PDF
Better screening and disease models needed Asher Mullard p151 | doi:10.1038/nrd.2016.47 PDF
BIOBUSINESS BRIEFS Regulatory watch: Impact of breakthrough therapy designation on cancer drug development Michael Shea, Linda Ostermann, Ryan Hohman, Samantha Roberts, Marina Kozak, Ryan Dull, Jeff Allen & Ellen Sigal p152 | doi:10.1038/nrd.2016.19 PDF
BIOBUSINESS BRIEFS Deal watch: MSD buys in to emerging epigenetic cancer target Megan Cully p153 | doi:10.1038/nrd.2016.20 PDF
AN AUDIENCE WITH Ian Tomlinson p154 | doi:10.1038/nrd.2016.22 Ian Tomlinson, former head of business development for GlaxoSmithKline and now chairman of the Apollo Therapeutics Fund, discusses a new model of pharmaceutical-academic partnership. PDF
FROM THE ANALYST'S COUCH What drives operational performance in clinical R&D? Michael Ringel et al. p155 | doi:10.1038/nrd.2016.2 This article presents a benchmarking analysis that identifies design parameters associated with improved performance in clinical R&D, and hence actions that companies can take to optimize their clinical development operations. PDF
RESEARCH HIGHLIGHTS Top Cancer: CARs: new models abound p157 | doi:10.1038/nrd.2016.44 PDF Neurodegenerative disease: Immunotherapy opportunity emerges for Alzheimer disease p158 | doi:10.1038/nrd.2016.38 PDF Biomaterials: Modified alginates provide a long-term disguise against the foreign body response p158 | doi:10.1038/nrd.2016.41 PDF Anticancer drugs: Putting the brakes on KRAS-G12C nucleotide cycling p159 | doi:10.1038/nrd.2016.40 PDF Lung disease: CXCR7 activation overrides lung fibrosis p160 | doi:10.1038/nrd.2016.25 PDF IN BRIEF Antibiotics: Antifungal agent blocks MRSA | Muscular dystrophy: Gene editing restores muscle function | Huntington disease: Blocking DREAM delays neurodegeneration PDF Drug Discovery JOBS of the week Postdoctoral Fellow Positions in Drug Delivery Northwestern University More Science jobs from Drug Discovery EVENT More science events from
Advertisement
This special Focus highlights the unprecedented insights gained into the regulatory mechanisms underlying nuclear reprogramming, pluripotency and cell identity, and looks at the progress and challenges in using embryonic stem (ES) cells and iPSCs for therapeutic applications. Available free online.  Produced with support from: Thermo Fisher Scientific
PERSPECTIVES		Top
OPINION G protein-coupled receptors as targets for anti-diabetic therapeutics Da Young Oh & Jerrold M. Olefsky p161 | doi:10.1038/nrd.2015.4 Modulators of glucagon-like peptide 1 (GLP1) and the resulting G protein-coupled receptor (GPCR) signalling have recently come to the fore of the treatment of type 2 diabetes. In this Opinion article, Oh and Olefsky discuss the potential for intervention with other GPCRs for the treatment of this disease, highlighting GPCR-mediated effects on insulin secretion, insulin sensitivity and inflammation. Abstract | Full Text | PDF
OPINION Integrin-based therapeutics: biological basis, clinical use and new drugs Klaus Ley, Jesus Rivera-Nieves, William J. Sandborn & Sanford Shattil p173 | doi:10.1038/nrd.2015.10 Members of the integrin family of receptors, which are involved in cell-cell adhesion, have been successfully targeted for cardiovascular disease, multiple sclerosis and inflammatory bowel disease. Ley and colleagues review the biological basis for the development of the next generation of integrin-targeted drugs, highlighting lessons learned from successes and failures. Abstract | Full Text | PDF
REVIEWS		Top
Gasotransmitters in cancer: from pathophysiology to experimental therapy Csaba Szabo p185 | doi:10.1038/nrd.2015.1 The gasotransmitters nitric oxide, carbon monoxide and hydrogen sulfide are involved in a large number of physiological processes. In this Review, the author explains how, in cancer, each of these gaseous mediators exhibits a biphasic pharmacological character, whereby increasing or decreasing gasotransmitter concentrations in the tumour can exert antitumour effects. Abstract | Full Text | PDF
Single-cell analysis tools for drug discovery and development James R. Heath, Antoni Ribas & Paul S. Mischel p204 | doi:10.1038/nrd.2015.16 Single-cell analysis tools are rapidly evolving, enabling cellular analyses at the genomic, transcriptomic and proteomic levels. Here, Heath and colleagues provide an overview of recently developed single-cell analysis technologies, discuss their biological applications and highlight their potential uses in drug discovery and development, focusing on the field of oncology. Abstract | Full Text | PDF
Corrigendum: Trends in breakthrough therapy designation Rachel R. Chizkov & Ryan P. Million p216 | doi:10.1038/nrd.2016.43 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.